NCT04332653 2026-03-09NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNeoImmuneTechPhase 1/2 Completed215 enrolled 30 charts
NCT04054752 2023-11-02Vaccine Response With NT-I7National Institutes of Health Clinical Center (CC)Phase 1 Withdrawn